Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds
- Invests in 100th Portfolio Company, Celebrates 25th Year of Franchise Operation - - Announces Promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners -
Kymera Therapeutics, Inc. ( KYMR ) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Kymera Revenue Drops 55 Percent in Q2
Kymera Therapeutics ( NASDAQ:KYMR ) , a biotechnology company recognized for its targeted protein degradation technology, released its second quarter 2025 results on August 11, 2025. The most notable news was a sharp decline in GAAP revenue for Q2 2025, with reported revenue of $11.48 million ...
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Reported positive KT-621 ( STAT6 ) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile ...
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
CorMedix ( CRMD ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025.
Kymera Therapeutics, Inc. ( KYMR ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF ( ARCA:IYF ) , Gilead Sciences ( NASDAQ:GILD )
Joseph M. Terranova names Gilead Sciences as his final trade. Brian Belski says Synovus Financial has 10 times earnings. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 PM ET.
NovoCure ( NVCR ) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Kymera Therapeutics Announces Pricing of $250 Million Public Offering - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., June 26, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
WATERTOWN, Mass., June 26, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public ...
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple ( NASDAQ:AAPL ) , Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut Apple Inc. AAPL price target from $240 to $230.
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences ( NASDAQ:GILD ) , Sanofi ( NASDAQ:SNY )
Gilead to pay Kymera up to $750 million for CDK2 degrader program; upfront and option payments total up to $85 million. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. Gilead Sciences, Inc. GILD and Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance ...
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week ( Jun 2-Jun 6 ) : Are The Others In Your Portfolio? - Applied Digital ( NASDAQ:APLD ) , Riot Platforms ( NASDAQ:RIOT )
Applied Digital soared 102.9% after signing a major infrastructure deal with AI firm CoreWeave. Kymera Therapeutics jumped 60.7% on strong KT-621 trial results and analyst upgrades from Morgan Stanley and B. Riley. Ready to turn the market's comeback into steady cash flow?
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday - Credo Technology Group ( NASDAQ:CRDO ) , Algonquin Power ( NYSE:AQN )
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of Signet Jewelers Limited SIG rose sharply during Tuesday's session after the company reported better-than-expected first-quarter financial results and raised its FY26 guidance.
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Applied Digital ( NASDAQ:APLD ) , Carnival ( NYSE:CCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Loop Capital raised Carnival Corporation CCL price target from $21 to $22.
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response - Kymera Therapeutics ( NASDAQ:KYMR )
KT-621 achieved >95% STAT6 degradation in blood and skin at doses ≥50 mg. Median TARC biomarker reduction of 37% observed by Day 14 across dose groups. Get access to the leaderboards pointing to tomorrow's biggest stock movers. Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Kymera Therapeutics ( NASDAQ:KYMR )
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile ...
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., May 30, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc.
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June ...
Kymera Therapeutics to Participate in Upcoming June Investor Conferences - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the ...
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
WATERTOWN, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside ...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression ...
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Kymera Therapeutics, Inc. ( KYMR ) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of 10.87% and 123.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug ...
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
WATERTOWN, Mass., May 07, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside ...
Why Kymera Therapeutics Stock Crushed it This Week
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics ( NASDAQ: KYMR ) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech sector. Investors were cheered by a pair of announcements published by the company.
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - Kymera Therapeutics ( NASDAQ:KYMR )
Watertown, Mass., April 24, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 ...
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Data from the BroADen Phase 1b atopic dermatitis ( AD ) patient trial expected to be reported in ...
Kymera Therapeutics ( KYMR ) Moves 13.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., April 09, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business ...
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
WATERTOWN, Mass., April 09, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as ...
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Kymera Therapeutics, Inc. ( KYMR ) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -15.79% and 43.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 ...
NAYA Biosciences Announces Nomination of New Board Members - Kymera Therapeutics ( NASDAQ:KYMR ) , Black Diamond Therapeutic ( NASDAQ:BDTX )
New board reflects company's added focus on oncology & autoimmune diseases
NAYA Biosciences Announces Nomination of New Board Members
SARASOTA, Fla. and MIAMI, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- NAYA Biosciences ( "NAYA" ) ( NASDAQ: NAYA ) , a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that its board of ...
Beyond Air, Inc. ( XAIR ) Reports Q3 Loss, Tops Revenue Estimates
Beyond Air (XAIR) delivered earnings and revenue surprises of 16.67% and 9.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Kymera Therapeutics ( NASDAQ:KYMR )
WATERTOWN, Mass., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will ...
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
WATERTOWN, Mass., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company ...
Kymera Provides Pipeline Objectives for 2025, Stock Gains
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
Kymera Therapeutics ( KYMR ) Moves 7.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - Kymera Therapeutics ( NASDAQ:KYMR )
KT-621 ( STAT6 ) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis ( AD ) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, ...
